Literature DB >> 8844977

Role of VLA-integrin receptor in invasion and metastasis of human fibrosarcoma cells.

R H Park1, I Yun.   

Abstract

Anti-invasive and anti-metastatic effects of anti-integrin antibodies (against VLA-alpha 2, alpha 4, beta 1) were examined on human fibrosarcoma cells using in vitro invasion assay in a reconstituted basement membrane (Matrigel) and experimental metastatic assay in a chick embryo. The effects of anti-integrin antibodies were compared with those of RGD-containing peptides (GRGDS), which have been known as effective inhibitors of tumor cell metastasis. Although slight differences in effective concentration among antibodies were observed, invasion and metastasis were significantly inhibited by anti-integrin antibodies. The results also showed partial inhibitory effect of GRGDS on the invasion and metastasis of human fibrosarcoma cells. These results indicate that integrin receptors mediating cell-cell/cell-extracellular matrix components interactions play a key role in the invasion and metastasis of human fibrosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8844977     DOI: 10.1016/0304-3835(96)04330-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

1.  Establishment of a nude mouse transplantable model of a human malignant fibrous histiocytoma of the mandible with high metastatic potential to the lung.

Authors:  Tsunenari Maeda; Susumu Hashitani; Yusuke Zushi; Emi Segawa; Noriaki Tanaka; Kazunari Sakurai; Masahiro Urade
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-04       Impact factor: 4.553

2.  Rapidly self-renewing human multipotent marrow stromal cells (hMSC) express sialyl Lewis X and actively adhere to arterial endothelium in a chick embryo model system.

Authors:  Harris E McFerrin; Scott D Olson; Miriam V Gutschow; Julie A Semon; Deborah E Sullivan; Darwin J Prockop
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.